Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $49.91 Consensus Target Price from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned a consensus rating of “Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $49.91.

Several research firms recently issued reports on DYN. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Robert W. Baird began coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $13.72 on Friday. The company has a 50-day simple moving average of $24.03 and a 200-day simple moving average of $32.55. Dyne Therapeutics has a one year low of $13.44 and a one year high of $47.45. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -3.85 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock valued at $606,476 in the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the period. RTW Investments LP raised its stake in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after purchasing an additional 431,503 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after purchasing an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. grew its stake in shares of Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares during the period. Finally, State Street Corp grew its stake in shares of Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after buying an additional 440,890 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.